This study sought to test whether insulin improves exercise ventilatory efficiency (VE/VCO 2 slope) and oxygen uptake at peak exercise (peak VO 2 ) in patients with type 2 diabetes-heart failure (HF) comorbidity. BACKGROUND In type 2 diabetes-HF comorbidity, depression of alveolar-capillary diffusion (DL CO ) correlates with deterioration of exercise VE/VCO 2 slope and peak VO 2 . Insulin potentiates DL CO in these patients.
Diabetes mellitus, as a comorbid disease, frequently confounds heart failure (HF) and adds significantly to its overall morbidity (1) (2) (3) . Poor glycemic control is associated with an increased risk of HF in type 2 diabetes (4,5); blood glucose
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control substantially reduces the risk of vascular complications (4) and improves endothelial function (6) . At the lung level, the alveolar-capillary membrane becomes a target structure of the coexisting diseases; left ventricular dysfunction causes a hydrostatic stress on the membrane (7) , and diabetes alters the alveolar and pulmonary capillary basal laminae (8) , resulting in a synergistic depression of the membrane conductance and gas exchange (9) . This alteration correlates with a joint adverse influence of these diseases on exercise ventilatory efficiency and peak exercise oxygen uptake (peak VO 2 ) (9) . In the setting of comorbidity, insulin may be beneficial. The hormone, in fact, reduces mortality in diabetes after acute myocardial infarction (10) , improves hemodynamics in HF without diabetes (11) , attenuates impedance to alveolar-capillary interface gas transfer in patients with diabetes (12) and even more in case of comorbidity (13) . There is no report concerning an influence of insulin on exercise ventilatory efficiency and oxygen uptake (VO 2 ). This does not seem to be an unrealistic possibility if one considers the relationship between these variables and gas exchange, and the effect insulin has on pulmonary gas transfer in patients with diabetes in addition to HF. The aims of this study were as follows:
1. to assess whether in cases with coexisting diseases, insulin ameliorates exercise performance and 2. to explore whether improvement in alveolar-capillary membrane conductance may have a role in these effects.
METHODS
Study population. This study includes 18 patients who were referred for evaluation of chronic HF. All gave written consent to the procedures, and the research was approved by the ethical review committee of the hospital. All had type 2 diabetes mellitus and none had participated in previous studies in our laboratory. Carboxyhemoglobin concentration was Ͻ2%, a value compatible with that of non-smoking urban dwellers. Glycosylated hemoglobin levels averaged 6.2 Ϯ 0.3% on therapy (the normal range in our laboratory is 4% to 5.5%). Hyperglycemia was controlled by diet alone (n ϭ 2), or plus sulfonylurea (n ϭ 9) or metformin (n ϭ 7). These were consecutive patients who were enrolled if they had chronic stable New York Heart Association functional class II to III HF from previous myocardial infarction (n ϭ 11) or idiopathic cardiomyopathy (n ϭ 7) (cardiac enlargement without a specific cause for left ventricular impairment); if ejection fraction was Ͻ35%; and if they were able to complete a maximal cardiopulmonary exercise test. Pulmonary function was not a selection measure. Patients were excluded if they had hypertension, pulmonary disease, or had smoked Ͼ10 cigarettes per day during one of the past five years (all had abstained from tobacco products for at least nine months before enrollment, and four patients had never smoked); if exercise was limited by symptoms other than dyspnea or fatigue and they developed electrocardiographic changes of myocardial ischemia on effort; if they had clinically evident distal symmetrical neuropathy, autonomic insufficiency, or renal impairment, all of which can alter exercise performance (9) . Patients who received betaadrenergic blocking agents or who, at Doppler velocimetry, presented with mitral regurgitation exceeding grade 2 on a scale of 0 to 5 also were not included. The antifailure treatments prescribed by the referring physicians included digoxin, loop diuretics, and angiotensin-converting enzyme inhibitors in all, nitrates in two, and aspirin in five. Exercise. Cycle ergometry exercise was performed in an upright position, using an individualized ramp protocol according to the preliminary assessment of the patient's functional capacity, to ensure a test duration of ϳ10 min and to avoid premature fatigue. Breath-by-breath gas exchange analysis was performed at rest and throughout exercise using a Sensor Medics Vmax 29C system (Yorba Linda, California). Respiratory gas was sampled continuously from a mouthpiece, and minute ventilation (VE), VO 2 , carbon dioxide output (VCO 2 ), and respiratory exchange ratio (RER) were calculated. The V-slope analysis was used to calculate the anaerobic threshold (AT). Ventilatory efficiency was assessed by calculating the slope of the increase in ventilation with respect to CO 2 production (VE/VCO 2 slope). Oxygen consumption at the AT, and the rate at which VO 2 increased per work rate (⌬VO 2 /⌬WR), as an indicator of aerobic efficiency, were also measured. The rate at which VO 2 increased per work rate was calculated for the progressively increasing exercise period beginning 1 min after WR started to increase. The delay of 1 min after the start of increase in WR was used to take into account the time constant for VO 2 to respond to the increasing WR (around 35 s for normal subjects) (17) . Peak VO 2 was determined by the highest VO 2 achieved during exercise. Age-, gender-, and weight-adjusted predicted VO 2 values were also determined. The maximal O 2 pulse was measured by dividing the highest VO 2 by the maximal heart rate. Echocardiography. Two-dimensional and Doppler echocardiography were performed by standard methods. Pulmonary artery systolic pressure, left ventricular end-systolic and end-diastolic chamber dimensions and left ventricular volume, by the area-length method (to measure ejection fraction), were quantitated by standard techniques. Stroke volume was calculated as the velocity time integral of the systolic velocity spectrum in the outflow tract multiplied by the subaortic area of the outflow tract. Protocol. All patients were admitted to the hospital, were maintained on their current drug treatment, and were fed a diet containing 160 g carbohydrate/day. Routine laboratory
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Guazzi et al. September 17, 2003 September 17, :1044 Insulin in HF-Diabetes Comorbidity work and cardiac evaluation were performed on the day of admission. On the second day, subjects were familiarized with exercise testing and performed a graded maximal exercise test to determine peak VO 2 . On the third day, they underwent an evaluation of pulmonary function including exchange capacity, pulmonary artery systolic pressure, ejection fraction and cardiac output, as well as an individualized exercise ramp test; these measurements were taken as the reference baseline parameters. On the following day, infusion studies were performed after a 12-h overnight fast and withdrawal of the morning oral hypoglycemic drugs, in a sitting position, in a quiet room. A catheter needle was inserted into an antecubital vein of each arm for infusions and blood drawing, respectively. After 30 min rest, 50 ml normal saline were infused intravenously, at a rate of 1.0 ml/min, that either contained or did not contain 10 IU of regular insulin (Humulin; Eli Lilly and Co., Indianapolis, Indiana). Glycemia was determined before infusion, at 10-min intervals during infusion, and 60 min after completion of the same. Blood glucose was kept at the baseline level during the experiment by administering, when necessary, intravenous 20% dextrose solution according to glycemia; the supplemented volume ranged between 20 and 80 ml. Serum potassium levels remained above 3.8 mEq/l in each patient during all phases of the study. Those incharged for exercise and those incharged for infusions were not admitted at the same time to the room where experiments were performed and were not allowed to communicate with each other. By this method the main outcome variables of the study were investigated in a blind fashion.
The short-term effects of insulin were investigated in all participants by re-evaluating lung and cardiac function at rest and exercise testing in the 60 min after infusion. On the following morning the same procedures were repeated while patients were switched to insulin or to inactive solution according to a random design. To determine the duration of the insulin effects, all measurements were repeated after a two-day washout period and were taken as the reference baseline parameters for the second part of the study, in which insulin and saline were given again according to the protocol already described, the only difference being a 6-h interval before the post-infusion evaluations. Statistical analysis. Values are expressed as mean Ϯ SD. Multiple comparison ANOVA test was used to compare the responses to saline and to insulin infusions. The two sets of baseline reference measurements performed in the two parts of the study were analyzed using the paired samples Student's t test.
The relationship between resting lung function tests and exercise parameters was assessed using the Pearson coefficient of correlation. A p value of Ͻ 0.05 was considered to be statistically significant. Statistical analyses were performed by means of Stata 7.0 package (Stata Corp., College Station, Texas). Table 1 and Table 2 show that in the baseline fasting glycemia and glycohemoglobin were moderately elevated, ejection fraction and cardiac index were depressed, systolic pulmonary pressure was raised, forced expiratory volume in 1 s and vital capacity were not consistent with airway obstruction, DL CO and DL CO /VA were reduced to 69.2 Ϯ 5.8% and to 63.8 Ϯ 10.9%, respectively, of predicted normal values (14) (below levels reported in the literature for HF alone) (18) . The proportion of diffusive resistance ascribable to alveolar-capillary interface averaged 74.6 Ϯ 7.4%. Peak VO 2 was compromised, and the VE/VCO 2 slope, in all patients but one, exceeded the value of 30, which is the upper normal limit (19) . The ⌬VO 2 /⌬WR, which reflects the oxygen utilized per unit increase in work rate and is an index of aerobic efficiency, was below the lower normal limit of 8.6 (20) and averaged 7.8 Ϯ 2.1 ml⅐W Ϫ1 ⅐min
RESULTS

Ϫ1
. At measurements accomplished in the 60 min after insulin infusion (Table 2 ) compared with those taken at baseline, systemic hemodynamics were steady, pulmonary systolic pressure was reduced. There was also a significant increase in carbon monoxide diffusion (DL CO , ϩ12.5%) and its membrane component (D M , ϩ21.6%). These changes, when expressed per unit of VA, were: DL CO /VA, ϩ18.9%; D M /VA, ϩ26.5%. Insulin also reduced the pulmonary capillary blood volume (V C , Ϫ16.3%) and (DL CO /D M , Ϫ9%). The individual values reported in Figure 1 show that in the great majority of patients there was an improvement of DL CO , D M , peak VO 2 , and a decrease of VE/VCO 2 slope. Compared with baseline reference measurements, insulin augmented peak VO 2 by 2.2 ml⅐kg Ϫ1 ⅐min Ϫ1 (ϩ13.5%) and reduced VE/VCO 2 slope by 18%. There was also an increase in time to anaerobic threshold (ϩ29.4%), O 2 pulse (ϩ12.3%), and ⌬VO 2 /⌬WR (ϩ21.2%). Saline alone, compared with baseline measurements, did not have any effect on the pulmonary gas exchange and exercise capacity.
Variations in peak VO 2 and VE/VCO 2 slope from baseline with insulin correlated significantly with those in DCM ϭ dilated cardiomyopathy; HF ϭ heart failure; IHD ϭ ischemic heart disease.
DL CO (Fig. 2 , r ϭ 0.67 p ϭ 0.002, and r ϭ Ϫ0.73, p Ͻ 0.001, respectively). We did not find a correlation of age, time from diabetes diagnosis, glycohemoglobin, and baseline fasting blood sugar with DL CO or D M . All changes were not present 24 h later at measurements performed in patients who were given saline alone as second test drug. On the contrary, in the second part of the study, measurements performed at 6 h after infusion showed that the improvement from baseline (reference values were not significantly different from those in the first part of the study) in DL CO , D M , peak VO 2 , VE/VCO 2 slope, and ⌬VO 2 /⌬WR was persistent and statistically significant (Table 3) .
DISCUSSION
The main information provided by this study is that in patients with coexistence of type 2 diabetes and HF, insulin was associated with amelioration in exercise ventilatory efficiency and VO 2 . Insulin also produced an improvement in the alveolar-capillary gas conductance that was significantly related with the decreased VE/VCO 2 slope and the increased peak VO 2 . These effects were not due to variations in glycemia.
Changes in DL CO versus changes in VE/VCO 2 slope.
Elevation of the hydrostatic forces and upregulation of sodium transport across the capillary endothelium by HF (16, 21) , and disturbances in microvascular permeability by diabetes (8, 22) , may concur to facilitate alveolar interstitial fluid accumulation and impedance to gas exchange. Insulin has the potential to reduce interstitial fluid accumulation and shorten the gas diffusion path in patients with diabetes or comorbidity, through an increase in inotropy (23) and a decrease of impedance to left ventricular ejection (23) (resulting in a reduction of the pulmonary hydrostatic forces), and by an enhancement of the defective release in diabetes of endothelium-derived nitric oxide and vasodilating prostaglandins (4,24 -26) . These substances are involved in the modulation of the pulmonary vascular tone and permeability and can reduce the tissue component of resistance to the oxygen transfer from the alveolus to its uptake by hemoglobin. How much of the benefit on gas exchange is due to a pulmonary vasodilating effect of insulin, which decreases pulmonary artery pressure, cannot be estimated. Previous observations, however, do not support a major role for changes in pulmonary hemodynamics. In fact, insulin is AT ϭ anaerobic threshold; DL CO ϭ carbon monoxide diffusion; D M ϭ alveolar-capillary membrane diffusing capacity; LV ϭ left ventricle; RER ϭ respiratory exchange ratio; VA ϭ alveolar volume; V C ϭ pulmonary capillary blood volume; VCO 2 ϭ carbon dioxide production; VE ϭ ventilation; VO 2 ϭ oxygen consumption; WR ϭ work rate.
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Guazzi et al. September 17, 2003 September 17, :1044 Insulin in HF-Diabetes Comorbidity not significantly effective on the impedance to gas transfer in HF patients without diabetes (13); hydralazine and isosorbide dinitrate, which are quite effective in reducing pulmonary artery pressure and arteriolar resistance in HF patients, fail to improve DL CO (27) . The possibilities should also be considered that saline, the vehicle used for insulin infusion, Figure 1 . Individual responses to insulin of the pulmonary gas exchange and exercise capacities. Filled circles are the means Ϯ SD. *p Ͻ 0.01 vs. baseline. DL CO ϭ lung diffusing capacity for carbon monoxide; D M ϭ diffusing capacity of the alveolar-capillary membrane; peak VO 2 ϭ oxygen consumption at peak exercise; V c ϭ pulmonary capillary volume available for gas exchange; VE/VCO 2 slope ϭ slope of the increase in ventilation with respect to carbon dioxide production; VO 2 AT ϭ oxygen consumption at the anaerobic threshold. Figure 2 . Individual changes in carbon monoxide diffusion (⌬DL CO ) vs. changes in peak exercise oxygen uptake (⌬peak VO 2 ) and in the slope of increase in ventilation with respect to carbon dioxide production (⌬VE/VCO 2 slope), after insulin infusion. may have depressed the lung diffusing capacity in HF patients (28) , or that aspirin counteracted the facilitating effect that angiotensin-converting enzyme inhibitors exert on alveolar-capillary membrane conductance (27) . These effects, however, would tend, if anything, to attenuate the response to insulin; therefore, they do not detract from our results. The origin of a steep slope of ventilation to CO 2 production on exercise may be multifactorial: increase of the ventilation required to overcome a large dead space, augmented central drive to ventilation originating from J-receptor activation in consequence of the distended interstitial space, bicarbonate buffering of accumulating lactic acid, reduced perfusion of ventilating lung, abnormal central or reflex chemosensitivity, overactive ergoreceptors, abnormal autonomic and baroreceptor control of the circulation (29, 30) . This study does not define which factor may be the target of the joint influence of diabetes and HF and whether insulin exerts a protective activity. However, the amelioration in alveolar-capillary conductance, as possibly mediated by reduction of lung interstitial space overdistention, and its correlation with the improvement in VE/VCO 2 slope are indicative of an involvement of the membrane effects of insulin in the ameliorated ventilatory efficiency. Likewise, the increase in time to AT (delayed reliance on anaerobic pathways for energy production) and in ⌬VO 2 /⌬WR (potentiated aerobic efficiency), are consistent with an interference of insulin with several mechanisms underlying the enhancement of VE/VCO 2 slope in patients with comorbidity. Changes in DL CO versus changes in peak VO 2 . Improvement in exercising skeletal muscle perfusion (11, 23) and glucose uptake (given the marked change in aerobic efficiency), and in cardiac output response to exercise (achievement of a higher O 2 pulse), may well explain the benefits of insulin on VO 2 . Insulin has a physiological role to vasodilate skeletal muscle vasculature, and this action is impaired in states of insulin resistance, such as type 2 diabetes and chronic HF (23) . The observed increase in ⌬VO 2 /⌬WR is consistent with an improvement in exercising muscle perfusion and/or an increase in cardiac output (increase in O 2 pulse). Using a similar protocol, in a comparable group of HF patients without diabetes, Parsonage et al. (11) have seen a beneficial central (increase in cardiac output) and peripheral (augmented forearm blood flow) effect of insulin. The extent of skeletal muscle perfusion can be an important determinant of insulin-mediated glucose uptake (31) . In our population, baseline peak RER averaged 1.02 and increased to 1.07 and 1.04, 60 min and 6 h after insulin, respectively. This is in favor of increased cellular glucose availability and improved substrate utilization.
Although the correlation between changes in DL CO and those in peak VO 2 may simply reflect association, a few compelling comments are in order. In HF, exercise raises the capillary pulmonary pressure and the fluid-flux transition (factors that underlie (7) alveolar-capillary membrane stress); the physiological increase in gas exchange during exercise is restrained at the level of the membrane (impeded increase in conductance because of excessive fluid filtration to the alveolar interstitium), and capillary recruitment for gas exchange is inadequate. Coexistence of diabetic disturbances in the microvessel permeability might enhance the excessive fluid passage in the interstitial space, which restrains gas conductance, and makes the capillary recruitment during exercise even more inadequate. In this setting, hyperventilation might help maintain oxygen alveolar tension at normal levels, but could precipitate premature 
